Potentiating antitumor immunity with αGC-loaded exosomes

Anticancer immunotherapy is a promising treatment modality since it bears the potential of being highly specific, but effective clinical applications are still under development. We have recently described an exosome-based strategy for co-delivery of α-galactosylceramide and a tumor-associated antig...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2013-10, Vol.2 (10), p.e26261-e26261
Main Authors: Gehrmann, Ulf, Hiltbrunner, Stefanie, Näslund, Tanja, Gabrielsson, Susanne
Format: Article
Language:English
Subjects:
Author's View
bone marrow-derived dendritic cells
exosomes
invariant natural killer T cells
ovalbumin
α-galactosylceramide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticancer immunotherapy is a promising treatment modality since it bears the potential of being highly specific, but effective clinical applications are still under development. We have recently described an exosome-based strategy for co-delivery of α-galactosylceramide and a tumor-associated antigen that synergistically potentiates tumor-specific adaptive immune responses while preventing the anergy of invariant natural killer T (iNKT) cells. We propose that the next generation of exosome-based immunotherapies should involve iNKT-cell ligands to induce a broad, amplified and sustainable antitumor immune response.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.26261